Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul;39(7):483-519.

Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia

Sapna Parmar, Khilna Patel, Javier Pinilla-Ibarz

Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia

Sapna Parmar et al. P T. 2014 Jul.

Abstract

Ibrutinib (Imbruvica): a novel targeted therapy for chronic lymphocytic leukemia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Btk signaling pathway Btk translocates to the plasma membrane by interacting with phosphatidylinositol-3,4,5 (PIP3) to become membrane-bound, where it undergoes sequential activation through transphosphorylation by Lyn and Syk kinases, followed by autophosphorylation. The downstream substrates of activated Btk and their associated signaling cascades are indicated.
See this image and copyright information in PMC

References

    1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29. - PubMed
    1. Chavez JC, Sahakian E, Pinilla-Ibarz J. Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evid. 2013;8:37–45. - PMC - PubMed
    1. Gribben JG. How I treat CLL up front. Blood. 2010;115:187–197. - PMC - PubMed
    1. Slager SL, Kay NE. Familial CLL: What does it mean to me? Clin Lymphoma Myeloma. 2009;9(Suppl 3):S194–S197. - PMC - PubMed
    1. Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2004;2004:163–183. - PubMed